➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Mallinckrodt
Moodys
Johnson and Johnson
AstraZeneca

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,722,702

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,722,702 protect, and when does it expire?

Patent 8,722,702 protects TURALIO and is included in one NDA.

This patent has forty-eight patent family members in thirty-five countries.

Summary for Patent: 8,722,702
Title:Compounds modulating c-fms and/or c-kit activity and uses therefor
Abstract: Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.
Inventor(s): Zhang; Jiazhong (Burlingame, CA), Ibrahim; Prabha N. (Mountain View, CA), Artis; Dean R. (Kensington, CA), Bremer; Ryan (Emeryville, CA), Wu; Guoxian (Foster City, CA), Nespi; Marika (Berkeley, CA), Zhang; Chao (Moraga, CA)
Assignee: Plexxikon Inc. (Berkeley, CA)
Application Number:13/776,547
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,722,702

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Daiichi Sankyo Inc TURALIO pexidartinib hydrochloride CAPSULE;ORAL 211810-001 Aug 2, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,722,702

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 063878   Start Trial
Australia 2007323644   Start Trial
Brazil PI0721137   Start Trial
Canada 2670362   Start Trial
Chile 2007003326   Start Trial
China 101605787   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Johnson and Johnson
Merck
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.